ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
88 hedge funds and large institutions have $134M invested in Adaptimmune Therapeutics in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
6% more capital invested
Capital invested by funds: $126M → $134M (+$7.45M)
0.98% less ownership
Funds ownership: 11.69% → 10.72% (-0.98%)
64% less call options, than puts
Call options by funds: $25K | Put options by funds: $70K
Holders
88
Holding in Top 10
2
Calls
$25K
Puts
$70K
Top Buyers
| 1 | +$5.82M | |
| 2 | +$4.71M | |
| 3 | +$4.52M | |
| 4 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$2.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$2.19M |
Top Sellers
| 1 | -$777K | |
| 2 | -$651K | |
| 3 | -$162K | |
| 4 |
VF
Virtu Financial
New York
|
-$96K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$51.7K |